Navigating the Evolving Acute Lymphoblastic Leukemia Treatment Paradigm

Jonathan Webster, MD, and Nikesh Shah, MD, provide a comprehensive overview of the evolving treatment landscape for acute lymphoblastic leukemia (ALL), with a focus on how frontline strategies and immunotherapy integration are reshaping patient outcomes. Across the program, they examine the role of blinatumomab in various clinical contexts, unpack how age and Philadelphia chromosome status influence therapeutic decision-making, and review emerging data for younger adults with BCR::ABL1–negative disease. Webster and Shah also highlight promising research directions and key studies to watch ahead of the 2025 ASH Annual Meeting, underscoring the rapidly advancing science driving future improvements in ALL care.